Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bepirovirsen Liver Biopsy Study
NCT07696520Phase 2Not yet recruiting
- Sponsor
- National University Health System
- Start
- Jul 2026
- Primary completion
- Dec 2027
- Countries
- 1
01
Overview
Phase 2, open-label trial of bepirovirsen in Chronic Hepatitis B (CHB) (2 arms), sponsored by National University Health System. Primary endpoint: Functional cure rate at 72 weeks. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
bepirovirsen
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT07696520.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07696520.